ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today the appointment of Andrew Gengos as President and Chief Executive Officer and member of the Board of Directors. With more than 20 years in the life science industry, Mr. Gengos’ experience includes executive leadership positions in both large and emerging companies, with broad expertise in corporate strategy, business development and transactions, including mergers and acquisitions, financing, operations, commercial planning and healthcare policy.
“ImmunoCellular’s board of directors and management team are confident that Andrew’s integrity, leadership qualities and breadth of experience in directing corporate strategy, forging successful partnerships and establishing alliances with the financial, business, medical and patient communities are exactly the mix of skills and attributes to advance our company to its next stages of maturation and value creation,” said John S. Yu, MD, ImmunoCellular’s Founder and Chief Scientific Officer, who has served as the company’s Interim Chief Executive Officer since August 2012. “We believe that Andrew’s deep interest in advancing the field of cancer immunotherapy, and his commitment to realizing the potential of our company’s technology platform and development pipeline, will be driving forces in establishing ImmunoCellular as a premier cancer vaccine company and building shareholder value.”
“Joining ImmunoCellular is an extraordinary opportunity to help build a leading biopharmaceutical company with the potential to transform the treatment of cancer,” said Mr. Gengos. “I believe that the company’s immunotherapy platform that targets both cancer cells and cancer stem cells represents a promising and innovative medical breakthrough. I am especially excited about the company’s lead clinical program in glioblastoma, and welcome the chance to continue to work in the field of neuroscience. I believe that ImmunoCellular has proven its ability to achieve impressive progress while working within a capital-efficient, virtual business model, and that the company is poised to achieve many important near-term clinical, financial and strategic milestones. I look forward to working with John, the board and the management team to continue to strengthen ImmunoCellular’s relationships with patients and other key stakeholders in the further development of our products and in the investor and analyst community, as well as to build the company’s visibility and reputation within the biotechnology and pharmaceutical industry.”